EP3838901B1 - Compound for treatment of rabies and method for treatment of rabies - Google Patents

Compound for treatment of rabies and method for treatment of rabies Download PDF

Info

Publication number
EP3838901B1
EP3838901B1 EP19849263.9A EP19849263A EP3838901B1 EP 3838901 B1 EP3838901 B1 EP 3838901B1 EP 19849263 A EP19849263 A EP 19849263A EP 3838901 B1 EP3838901 B1 EP 3838901B1
Authority
EP
European Patent Office
Prior art keywords
optionally substituted
alkyl
aryl
bnzl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP19849263.9A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3838901A1 (en
EP3838901A4 (en
Inventor
Hiroyuki Kouji
Kentaro Yamada
Akira Katoh
Toshimasa ISHIZAKI
Shigeru Matsuoka
Akira Nishizono
Tadashi Mishina
Atsushi Yoshimori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Irimajiri Therapeutics Inc
Original Assignee
Irimajiri Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irimajiri Therapeutics Inc filed Critical Irimajiri Therapeutics Inc
Publication of EP3838901A1 publication Critical patent/EP3838901A1/en
Publication of EP3838901A4 publication Critical patent/EP3838901A4/en
Application granted granted Critical
Publication of EP3838901B1 publication Critical patent/EP3838901B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present disclosure relates to a novel fused tricyclic compound that is useful as a medicament, an enantiomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof. More specifically, the present disclosure relates to a pharmaceutical composition comprising the fused tricyclic compound or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof. The present disclosure also relates to a therapeutic agent comprising the fused tricyclic compound or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
  • Rabies is an infection induced by a rabies virus.
  • the mortality after the onset in humans is almost 100%. While over 15 million people worldwide are vaccinated post-exposure for the prophylaxis of rabies every year, the worldwide number of fatalities due to rabies is about 55000 annually.
  • An effective therapeutic method for rabies still has not been established. There is still a demand for the establishment thereof.
  • the present disclosure provides a compound and a method for the treatment of rabies. Any references to methods of treatment in the subsequent paragraphs of this description are to be interpreted as references to the compounds, pharmaceutical compositions and medicaments of the present invention for use in a method for treatment of the human (or animal) body by therapy (or for diagnosis).
  • the present disclosure provides the following items.
  • a compound represented by formula IB or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein
  • R 1 , R 2 and R 3 are each independently C 1-6 alkyl, hydroxy-substituted C 1-6 alkyl, carbamoyl-substituted C 1-6 alkyl, amino-substituted C 1-6 alkyl, amidinoamino-substituted C 1-6 alkyl, carboxy-substituted C 1-6 alkyl, C 6-10 aryl C 1-6 alkyl, C 1-4 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C 1-6 alkyl, C 1-4 alkyl-substituted C 6-10 aryl C 1-6 alkyl, hydroxy-substituted C 6-10 aryl C 1-6 alkyl, halogen-substituted C 6-10 aryl C 1-6 alkyl, C 1-4 alkoxy-
  • R 1 , R 2 and R 3 are each independently C 1-6 alkyl, hydroxy-substituted C 1-6 alkyl, carbamoyl-substituted C 1-6 alkyl, amino-substituted C 1-6 alkyl, amidinoamino-substituted C 1-6 alkyl, carboxy-substituted C 1-6 alkyl, C 6-10 aryl C 1-6 alkyl, C 1-4 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C 1-6 alkyl, C 1-4 alkyl-substituted C 6-10 aryl C 1-6 alkyl, hydroxy-substituted C 6-10 aryl C 1-6 alkyl, halogen-substituted C 6-10 aryl C 1-6 alkyl, C 1-4 alkoxy-
  • R 4 is hydrogen, optionally substituted C 1-6 alkyl, optionally substituted C 1-6 alkylcarbonyl, optionally substituted C 6-10 aryl C 1-6 alkylcarbonyl, optionally substituted C 6-10 arylcarbonyl, optionally substituted C 1-6 alkoxycarbonyl, optionally substituted C 6-10 aryl C 1-6 alkoxycarbonyl, carbamoyl, optionally substituted C 1-6 alkylcarbamoyl, or optionally substituted C 6-10 aryl C 1-6 alkylcarbamoyl.
  • R 1 , R 2 and R 3 are each independently optionally substituted alkyl or optionally substituted arylalkyl.
  • R 1 , R 2 and R 3 are each independently optionally substituted C 1-6 alkyl or optionally substituted C 6-10 aryl C 1-6 alkyl.
  • R 1 , R 2 and R 3 are each independently C 1-6 alkyl, C 6-10 aryl C 1-6 alkyl, C 1-4 alkyl-substituted C 6-10 aryl C 1-6 alkyl, halogen-substituted C 6-10 aryl C 1-6 alkyl, C 1-4 alkoxy-substituted C 6-10 aryl C 1-6 alkyl, or (optionally substituted amino) -C 6-10 aryl C 1-6 alkyl.
  • R 1 and R 3 are each independently alkyl or optionally substituted benzyl, and R 2 is optionally substituted benzyl.
  • R 1 and R 3 are each independently C 1-6 alkyl, benzyl, C 1-4 alkyl-substituted benzyl, chloro-substituted benzyl, C 1-4 alkoxy-substituted benzyl, or amino-substituted benzyl, and R 2 is benzyl or chloro-substituted benzyl.
  • R 1 and R 3 are each independently isobutyl, isopentyl, 4-(dimethylamino)benzyl, 4-methylbenzyl, 4-methoxybenzyl, 3-chlorobenzyl, 4-chlorobenzyl, or 3,4-dichlorobenzyl, and R 2 is benzyl, 3-chlorobenzyl, or 3,4-dichlorobenzyl.
  • R 4 is hydrogen, C 1-6 alkyl, C 1-6 alkylcarbonyl, C 6-10 arylcarbonyl, C 6-10 aryl C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, C 6-10 aryl C 1-6 alkoxycarbonyl, carbamoyl, C 1-6 alkylcarbamoyl, or C 6-10 aryl C 1-6 alkylcarbamoyl.
  • R 4 is hydrogen, C 1-6 alkyl, C 1-6 alkylcarbonyl, C 6-10 arylcarbonyl, or C 1-6 alkoxycarbonyl.
  • R 4 is hydrogen, C 1-4 alkyl, C 1-4 alkylcarbonyl, C 6 arylcarbonyl, C 6 aryl C 1-4 alkylcarbonyl, C 1-4 alkoxycarbonyl, C 6 aryl C 1-4 alkoxycarbonyl, carbamoyl, C 1-4 alkylcarbamoyl, or C 6 aryl C 1-4 alkylcarbamoyl.
  • R 4 is hydrogen, C 1-4 alkyl, C 1-4 alkylcarbonyl, C 6 arylcarbonyl, or C 1-4 alkoxycarbonyl.
  • R 4 is hydrogen, methyl, ethyl, acetyl, benzoyl, methoxycarbonyl, tert-butoxycarbonyl, or propylcarbamoyl.
  • R 4 is hydrogen, methyl, ethyl, acetyl, benzoyl, methoxycarbonyl, or tert-butoxycarbonyl.
  • R 2 is C 1-4 alkyl, hydroxy-substituted C 1-4 alkyl, carbamoyl-substituted C 1-4 alkyl, amino-substituted C 1-4 alkyl, amidinoamino-substituted C 1-4 alkyl, carboxy-substituted C 1-4 alkyl, C 6-10 aryl C 1-4 alkyl, C 1-4 alkoxycarbonyl-substituted 5-to 10-membered heteroaryl C 1-4 alkyl, C 1-4 alkyl-substituted C 6-10 aryl C 1-4 alkyl, hydroxy-substituted C 6-10 aryl C 1-4 alkyl, halogen-substituted C 6-10 aryl C 1-4 alkyl, C 1-4 alkoxy-substituted C 6-10
  • R 2 is isopropyl, 1-methylpropyl, isobutyl, isopentyl, n-hexyl, hydroxymethyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,4-dichlorobenzyl,
  • R 2 is isobutyl, 2-hydroxyethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 2-(tert-butoxy)-2-oxoethyl, 4-((tert-butoxycarbonyl)amino)butyl, (tetrahydro-2H
  • R 2 is 1-methylpropyl, isopropyl, isobutyl, isopentyl, n-hexyl, benzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, carbamoylethyl, 3-(amidinoamino)propyl, hydroxymethyl, 2-hydroxyethyl, phenethyl, naphthalen-1-ylmethyl, or cyclohexylmethyl.
  • R 2 is isopropyl, isobutyl, isopentyl, benzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, 2-hydroxyethyl, phenethyl, naphthalen-1-ylmethyl, or n-hexyl.
  • R 2 is 1-methylpropyl, isopropyl, isobutyl, benzyl, 4-hydroxybenzyl, 2-carboxyethyl, 3-(amidinoamino)propyl, or naphthalen-1-ylmethyl.
  • R 1 is C 1-6 alkyl, hydroxy-substituted C 1-4 alkyl, carbamoyl-substituted C 1-4 alkyl, amino-substituted C 1-6 alkyl, amidinoamino-substituted C 1-4 alkyl, carboxy-substituted C 1-4 alkyl, C 1-4 alkoxycarbonyl-substituted C 1-4 alkyl, C 6-10 aryl C 1-4 alkyl, hydroxy-substituted C 6-10 aryl C 1-4 alkyl, C 1-4 alkoxy-substituted C 6-10 aryl C 1-4 alkyl, halo-substituted C 6-10 aryl C 1-4 alkyl, or C 5-6 cycloalkyl C 1-4 alkyl.
  • R 1 is methyl, isopropyl, isobutyl, isopentyl, n-hexyl, 3-amino-3-oxopropyl, 3-(tert-butoxy)-3-oxopropyl, benzyl, naphthalen-1-ylmethyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, 4-fluorobenzyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3,4-dichlorobenzyl, naphthalen-1-ylmethyl, phenethyl, hydroxymethyl, 2-hydroxyethyl, or cyclohexylmethyl.
  • R 1 is methyl, isobutyl, isopentyl, 3-(tert-butoxy)-3-oxopropyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3,4-dichlorobenzyl, or cyclohexylmethyl.
  • R 1 is isopropyl, isobutyl, isopentyl, n-hexyl, cyclohexylmethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, carbamoylethyl, 3-(amidinoamino)propyl, hydroxymethyl, or hydroxyethyl.
  • R 1 is isobutyl, isopentyl, cyclohexylmethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, or hydroxyethyl.
  • R 1 is isobutyl, benzyl, 4-hydroxybenzyl, 2-carboxyethyl, 3-(amidinoamino)propyl, or naphthalen-1-ylmethyl.
  • R 3 is C 1-4 alkyl, hydroxy-substituted C 1-4 alkyl, carbamoyl-substituted C 1-4 alkyl, C 1-4 alkoxycarbonyl-substituted C 1-4 alkyl, amino-substituted C 1-4 alkyl, amidinoamino-substituted C 1-4 alkyl, carboxy-substituted C 1-4 alkyl, C 6-10 aryl C 1-4 alkyl, C 1-4 alkyl-substituted C 6-10 aryl C 1-4 alkyl, hydroxy-substituted C 6-10 aryl C 1-4 alkyl, or C 5-6 cycloalkyl C 1-4 alkyl.
  • the compound or an enantiomer thereof, or a salt thereof, or a solvate thereof according to any one of the preceding items, which is isopropyl, isobutyl, isopentyl, n-hexyl, hydroxymethyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 3-methylbenzyl, 4-methylbenzyl, 3-methoxy-3-oxopropyl, 4-((tert-butoxycarbonyl)amino)butyl, or cyclohexylmethyl.
  • R 3 is isobutyl, isopentyl, 3-amino-3-oxopropyl, 3-methoxy-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-((tert-butoxycarbonyl)amino)butyl, or cyclohexylmethyl.
  • R 3 is isopropyl, isobutyl, isopentyl, n-hexyl, cyclohexylmethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, carbamoylethyl, 3-(amidinoamino)propyl, hydroxymethyl, or hydroxyethyl.
  • R 3 is isobutyl, isopentyl, benzyl, phenethyl, 4-hydroxybenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, hydroxymethyl, or naphthalen-1-ylmethyl.
  • R 3 is isobutyl, benzyl, 4-hydroxybenzyl, 2-carboxyethyl, 3-(amidinoamino)propyl, or naphthalen-1-ylmethyl.
  • R 1 is C 1-6 alkyl or C 6-10 aryl C 1-6 alkyl
  • R 2 and R 3 are each independently C 1-6 alkyl or optionally substituted C 6-10 aryl C 1-6 alkyl.
  • R 1 is isobutyl, isopentyl, or benzyl
  • R 2 is isobutyl, benzyl, phenethyl, 3-methylbenzyl, 4-methylbenzyl, or 3,4-dichlorobenzyl
  • R 3 is isobutyl, benzyl, phenethyl, 3-methylbenzyl, or 4-methylbenzyl.
  • the compound of formula IF is a compound selected from the group consisting of IF-1, IF-2, IF-3, IF-4, IF-5, IF-6, IF-7, IF-8, IF-9, IF-10, IF-11, IF-12, IF-13, IF-14, IF-15, IF-16, IF-17, IF-18, IF-19, IF-20, IF-22, IF-23, IF-24, IF-25, IF-26, IF-27, IF-28, IF-29, IF-30, IF-31, IF-32, IF-33, IF-34, IF-35, IF-36, IF-38, IF-39, IF-40, IF-41, IF-42, IF-43, IF-44, IF-45, IF-46, IF-47, IF
  • the compound of formula IB is a compound selected from the group consisting of IB-1, IB-2, IB-3, IB-4, IB-5, IB-6, IB-7, IB-8, IB-9, IB-10, IB-11, IB-12, IB-13, IB-14, IB-15, IB-16, IB-17, IB-18, IB-19, IB-20, IB-21, IB-22, IB-23, IB-24, IB-25, IB-26, IB-27, IB-28, IB-29, IB-30, IB-31, IB-32, IB-33, IB-34, IB-35, IB-36, IB-37, IB-38, IB-39, IB-40, IB-41, IB-42, IB-43, IB-44, IB-45, IB-
  • R 1 , R 2 and R 3 are each independently optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, or optionally substituted cycloalkylalkyl.
  • R 1 , R 2 and R 3 are each independently optionally substituted C 1-6 alkyl, optionally substituted C 6-10 aryl C 1-6 alkyl, optionally substituted 5- to 10-membered heteroaryl C 1-6 alkyl, or optionally substituted C 3-6 cycloalkyl C 1-6 alkyl.
  • R 1 , R 2 and R 3 are each independently C 1-6 alkyl, hydroxy-substituted C 1-6 alkyl, carbamoyl-substituted C 1-6 alkyl, amino-substituted C 1-6 alkyl, amidinoamino-substituted C 1-6 alkyl, carboxy-substituted C 1-6 alkyl, C 6-10 aryl C 1-6 alkyl, C 1-4 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C 1-6 alkyl, C 1-4 alkyl-substituted C 6-10 aryl C 1-6 alkyl, hydroxy-substituted C 6-10 aryl C 1-6 alkyl, halogen-substituted C 6-10 aryl C 1-6 alkyl, C 1-4 alkoxy-
  • R 1 , R 2 and R 3 are each independently C 1-6 alkyl, hydroxy-substituted C 1-6 alkyl, carbamoyl-substituted C 1-6 alkyl, amino-substituted C 1-6 alkyl, amidinoamino-substituted C 1-6 alkyl, carboxy-substituted C 1-6 alkyl, C 6-10 aryl C 1-6 alkyl, C 1-4 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C 1-6 alkyl, C 1-4 alkyl-substituted C 6-10 aryl C 1-6 alkyl, hydroxy-substituted C 6-10 aryl C 1-6 alkyl, halogen-substituted C 6-10 aryl C 1-6 alkyl, C 1-4 alkoxy-
  • R 1 , R 2 and R 3 are each independently optionally substituted alkyl or optionally substituted arylalkyl.
  • R 1 , R 2 and R 3 are each independently optionally substituted C 1-6 alkyl or optionally substituted C 6-10 aryl C 1-6 alkyl.
  • R 2 is C 1-4 alkyl, hydroxy-substituted C 1-4 alkyl, carbamoyl-substituted C 1-4 alkyl, amino-substituted C 1-4 alkyl, amidinoamino-substituted C 1-4 alkyl, carboxy-substituted C 1-4 alkyl, C 6-10 aryl C 1-4 alkyl, C 1-4 alkoxycarbonyl-substituted 5-to 10-membered heteroaryl C 1-4 alkyl, C 1-4 alkyl-substituted C 6-10 aryl C 1-4 alkyl, hydroxy-substituted C 6-10 aryl C 1-4 alkyl, halogen-substituted C 6-10 aryl C 1-4 alkyl, C 1-4 alkoxy-substituted C 6-10
  • R 2 is isopropyl, 1-methylpropyl, isobutyl, isopentyl, n-hexyl, hydroxymethyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,4-dichlorobenzyl,
  • R 2 is isobutyl, 2-hydroxyethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 2-(tert-butoxy)-2-oxoethyl, 4-((tert-butoxycarbonyl)amino)butyl, (tetrahydro-2H
  • R 2 is isopropyl, isobutyl, isopentyl, benzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, hydroxyethyl, phenethyl, naphthalen-1-ylmethyl, or n-hexyl.
  • R 2 is isopropyl, 1-methylpropyl, isobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3-(tertbutoxy)-3-oxopropyl, or
  • R 1 is C 1-6 alkyl, hydroxy-substituted C 1-4 alkyl, carbamoyl-substituted C 1-4 alkyl, amino-substituted C 1-6 alkyl, amidinoamino-substituted C 1-4 alkyl, carboxy-substituted C 1-4 alkyl, C 1-4 alkoxycarbonyl-substituted C 1-4 alkyl, C 6-10 aryl C 1-4 alkyl, hydroxy-substituted C 6-10 aryl C 1-4 alkyl, C 1-4 alkoxy-substituted C 6-10 aryl C 1-4 alkyl, halo-substituted C 6-10 aryl C 1-4 alkyl, or C 5-6 cycloalkyl C 1-4 alkyl.
  • R 1 is methyl, isopropyl, isobutyl, isopentyl, n-hexyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, hydroxymethyl, cyclohexylmethyl, or
  • R 1 is methyl, isobutyl, isopentyl, 3-(tert-butoxy)-3-oxopropyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3,4-dichlorobenzyl, or cyclohexylmethyl.
  • R 1 is isobutyl, isopentyl, cyclohexylmethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, or hydroxyethyl.
  • R 1 is isobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tertbutoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, or
  • R 3 is C 1-4 alkyl, hydroxy-substituted C 1-4 alkyl, carbamoyl-substituted C 1-4 alkyl, C 1-4 alkoxycarbonyl-substituted C 1-4 alkyl, amino-substituted C 1-4 alkyl, amidinoamino-substituted C 1-4 alkyl, carboxy-substituted C 1-4 alkyl, C 6-10 aryl C 1-4 alkyl, C 1-4 alkyl-substituted C 6-10 aryl C 1-4 alkyl, hydroxy-substituted C 6-10 aryl C 1-4 alkyl, or C 5-6 cycloalkyl C 1-4 alkyl.
  • R 3 is isopropyl, isobutyl, isopentyl, n-hexyl, hydroxymethyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 4-(tert-butoxy)benzyl, 3-methoxy-3-oxopropyl, 3-(tert-butoxy)-3-oxopropyl, 4-((tert-butoxycarbonyl)amino)butyl, cyclohexylmethyl, or
  • R 3 is isobutyl, isopentyl, 3-amino-3-oxopropyl, 3-methoxy-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-((tert-butoxycarbonyl)amino)butyl, or cyclohexylmethyl.
  • R 3 is isobutyl, isopentyl, benzyl, phenethyl, 4-hydroxybenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, hydroxymethyl, or naphthalen-1-ylmethyl.
  • R 3 is isobutyl, 2-carboxyethyl, 3-(amidinoamino)propyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tertbutoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, or
  • R 1 is C 1-6 alkyl or C 6-10 aryl C 1-6 alkyl
  • R 2 and R 3 are each independently C 1-6 alkyl or optionally substituted C 6-10 aryl C 1-6 alkyl.
  • R 1 , R 2 , and R 3 are each independently C 1-6 alkyl or optionally substituted C 6-10 aryl C 1-6 alkyl.
  • R 1 , R 2 , and R 3 are each independently C 1-6 alkyl, C 6-10 aryl C 1-6 alkyl, C 1-4 alkyl-substituted C 6-10 aryl C 1-6 alkyl, halogen-substituted C 6-10 aryl C 1-6 alkyl, C 1-4 alkoxy-substituted C 6-10 aryl C 1-6 alkyl, or (optionally substituted amino) -C 6-10 aryl C 1-6 alkyl.
  • R 1 is C 1-6 alkyl or C 6 aryl C 1-4 alkyl
  • R 2 is C 1-6 alkyl or C 1-4 alkyl-substituted benzyl
  • R 3 is C 1-6 alkyl or C 6 aryl C 1-4 alkyl.
  • R 1 is isobutyl, benzyl, 4-(dimethylamino)benzyl, 4-methylbenzyl, 4-tert-butylbenzyl, 4-methoxybenzyl, 3-chlorobenzyl, 4-chlorobenzyl, or 3,4-dichlorobenzyl
  • R 2 is isobutyl, benzyl, naphthalen-1-ylmethyl, 4-methylbenzyl, 4-chlorobenzyl, or 3,4-dichlorobenzyl
  • R 3 is isobutyl, isopentyl, or benzyl.
  • R 1 is isobutyl, isopentyl, or benzyl
  • R 2 is isobutyl, benzyl, phenethyl, 3-methylbenzyl, 4-methylbenzyl, or 3,4-dichlorobenzyl
  • R 3 is isobutyl, benzyl, phenethyl, 3-methylbenzyl, or 4-methylbenzyl.
  • An antiviral agent for a virus in the Lyssavirus genus comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof.
  • the antiviral agent according to any one of the preceding items, wherein the virus in the Lyssavirus genus comprises a rabies virus.
  • a medicament comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, or the antiviral agent according to any one of the preceding items.
  • the medicament according to any one of the preceding items which is a prophylactic agent or a therapeutic agent for rabies.
  • a pharmaceutical composition comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, or the antiviral agent according to any one of the preceding items, and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition for use in the prophylaxis or treatment of rabies comprising the compound according to any one of the preceding items or a pharmaceutically acceptable salt thereof, or the antiviral agent according to any one of the preceding items, and a pharmaceutically acceptable carrier.
  • the compounds of the present disclosure exhibit an excellent antiviral action on viruses in the Lyssavirus genus including the rabies virus. Therefore, the compounds of the present disclosure are useful as a therapeutic agent and/or prophylactic agent for rabies.
  • group refers to a monovalent group, unless especially noted otherwise. Examples of a group that is not a monovalent group include alkylene group (divalent) and the like. The term “group” may also be abbreviated in the following description of substituents or the like.
  • the number of substituents when a group is defined as “optionally substituted” or “substituted” is not particularly limited as long as it is substitutable and is one or more. The description for each group is also applicable when the substituent is a part of or a substituent on another substituent, unless specifically noted otherwise.
  • any portion of the group can be substituted.
  • “optionally substituted arylalkyl” and “substituted arylalkyl” can have the aryl moiety substituted, the alkyl moiety substituted, or both the aryl moiety and the alkyl moiety substituted.
  • substituents used when "optionally substituted” can be selected from substituent group ⁇ consisting of the following, and substitution can be performed with 1 to 5 of the same or different substituents. While the types of atoms within a substituent associated with attachment are not particularly limited by the type of substituent, if the atom to which a substituent attaches is an oxygen atom, a nitrogen atom, or a sulfur atom, the substituent is limited to those with an attaching atom that is a carbon atom from the following substituents.
  • Substituent group ⁇ includes
  • hydrogen of any hydroxyl group in substituent groups ⁇ and ⁇ is optionally substituted with a protecting group.
  • Substituent group ⁇ preferably includes
  • hydrogen of any hydroxy group in substituent groups ⁇ and ⁇ is optionally substituted with a protecting group.
  • Substituent group ⁇ more preferably includes
  • hydrogen of any hydroxyl group in substituent groups ⁇ and ⁇ is optionally substituted with a protecting group.
  • C 1-6 means that the number of carbon atoms is 1 to 6. The same applies to other numbers.
  • C 1-4 means that the number of carbon atoms is 1 to 4
  • C 1-3 means that the number of carbon atoms is 1 to 3.
  • heteroatom refers to atoms other than carbon atoms and hydrogen atoms such as oxygen atoms, nitrogen atoms, and sulfur atoms.
  • halogen atom is an atom belonging to the halogen group, referring to a fluorine atom, chlorine atom, bromine atom, iodine atom, or the like, and is preferably a fluorine atom or chlorine atom, and still more preferably a fluorine atom.
  • a “halogen atom” is also referred to as “halogen” or "halo”.
  • hydroxyl group is a monovalent group of -OH. This group is also referred to as a “hydroxy group” or "hydroxy”.
  • Carboxyl group is a monovalent group of -COOH. This group is also referred to as a “carboxy group”, “carboxy”, or “carboxyl”.
  • cyano group is a monovalent group of -CN.
  • amino is a monovalent group of -NH 2 . This group is also referred to as an "amino group”.
  • alkyl refers to a linear or branched saturated aliphatic hydrocarbon group.
  • C 1-6 alkyl is an alkyl group with 1 to 6 carbon atoms, which is preferably “C 1-4 alkyl", more preferably “C 1-3 alkyl”, and stil more preferably “C 1-2 alkyl”.
  • Specific examples of "C 1-4 alkyl” include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, and the like.
  • C 1-6 alkyl include, but are not limited to, C 1-4 alkyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1,2-dimethylpropyl, n-hexyl, and the like.
  • alkenyl refers to a linear or branched unsaturated aliphatic hydrocarbon group comprising at least one carbon-carbon double bond.
  • C 2-6 alkenyl is an alkenyl group with 2 to 6 carbon atoms. Preferred examples thereof include “C 2-4 alkenyl”. Specific examples of “C 2-6 alkenyl” include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-1-propylenyl, 2-methyl-2-propylenyl, and the like.
  • alkynyl refers to a linear or branched unsaturated aliphatic hydrocarbon group comprising at least one carbon-carbon triple bond.
  • C 2-6 alkynyl is an alkynyl group with 2 to 6 carbon atoms. Preferred examples thereof include “C 2-4 alkynyl”. Specific examples of “C 2-6 alkynyl” include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 1-methyl-2-propynyl, 3-butynyl, 1-pentynyl, 1-hexynyl, and the like.
  • aryl refers to a monovalent group of a monocyclic or bicyclic aromatic hydrocarbon ring.
  • C 6-10 aryl refers to an aryl group with 6 to 10 carbon atoms. Examples of “aryl” include, but are not limited to, C 6 aryl, C 10 aryl, and the like. Specific examples of C 6 aryl include, but are not limited to, phenyl and the like. Specific examples of C 10 aryl include, but are not limited to, 1-naphthyl, 2-naphthyl, and the like.
  • arylalkyl refers to alkyl substituted with at least one aryl.
  • C 6-10 aryl C 1-6 alkyl refers to C 1-6 alkyl substituted with at least one C 6-10 aryl.
  • Specific examples of C 6-10 aryl C 1-6 alkyl include, but are not limited to, benzyl (phenyl-CH 2 -), phenethyl(phenyl-CH 2 CH 2 -), naphthalen-1-ylmethyl, naphthalen-2-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(naphthalen-2-yl)ethyl, and the like.
  • (optionally substituted amino)-arylalkyl refers to arylalkyl substituted with an optionally substituted amino group, wherein the alkyl group, the aryl group, or both is substituted with an amino group.
  • An amino group of such an arylalkyl group may be unsubstituted, or substituted with 1, 2, or 3 substituents, such as optionally substituted alkyl (e.g., unsubstituted C 1-6 alkyl, C 3-6 cycloalkyl-C 1-6 alkyl, C 3-6 cycloalkylcarbonyl, or the like).
  • Examples of (optionally substituted amino)-C 6 -10 aryl C 1-6 alkyl include, but are not limited to, 4-(dimethylamino)benzyl, 4-((cyclopentylmethyl)amino)benzyl, 4-((cyclopentylcarbonyl)amino)benzyl, 4-((2-carbamoylethyl)carbonylamino)benzyl, and the like.
  • C 6-10 aryl moiety of "C 6-10 arylthio” is defined the same as the aforementioned C 6-10 aryl.
  • Preferred examples of “C 6-10 arylthio” include “C 6 or C 10 arylthio”.
  • Specific examples of "C 6-10 aryloxy” include, but are not limited to, phenylthio, 1-naphthylthio, 2-naphthylthio, and the like.
  • C 6-10 aryl sulfonyl refers to sulfonyl substituted with the aforementioned “C 6-10 aryl”.
  • C 6-10 aryl sulfonyl is preferably “C 6 or C 10 aryl sulfonyl”.
  • Specific examples of “C 6-10 aryl sulfonyl” include, but are not limited to, phenylsulfonyl, 1-naphthylsulfonyl, 2-naphthylsulfonyl, and the like.
  • heteroaryl refers to a monovalent group of a monocyclic or bicyclic aromatic heterocycle comprising 1 to 4 same or different heteroatoms selected from the group consisting of an oxygen atom, nitrogen atom, and sulfur atom.
  • 5- to 6-membered heteroaryl refers to a monovalent group of a monocyclic aromatic heterocycle consisting 5 to 6 atoms, comprising 1 to 4 same or different heteroatoms selected from the group consisting of an oxygen atom, nitrogen atom, and sulfur atom.
  • 5- to 6-membered heteroaryl include, but are not limited to, pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, tetrazolyl, pyridyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, and the like.
  • 5- to 10-membered heteroaryl refers to a monovalent group of a monocyclic or bicyclic aromatic heterocycle consisting of 5 to 10 atoms, comprising 1 to 4 same or different heteroatoms selected from the group consisting of an oxygen atom, nitrogen atom, and sulfur atom.
  • 5- to 10-membered heteroaryl include, but are not limited to, 5- to 6-membered heteroaryl, quinolyl, isoquinolyl, naphthyridinyl, quinoxalinyl, cinnolinyl, quinazolinyl, phthalazinyl, imidazopyridyl, imidazothiazolyl, imidazooxazolyl, benzothiazolyl, benzooxazolyl, benzoimidazolyl, indolyl, isoindolyl, indazolyl, pyrrolopyridyl, thienopyridyl, furopyridyl, benzothiadiazolyl, benzooxadiazolyl, pyridopyrimidinyl, benzofuryl, benzothienyl, benzo[1,3]dioxole, thienofuryl, chromenyl, chromanyl, coumarin
  • heteroarylalkyl refers to alkyl substituted with at least one heteroaryl.
  • “5- to 10-membered heteroaryl C 1-6 alkyl” refers to C 1-6 alkyl substituted with at least one 5- to 10-membered heteroaryl.
  • Specific examples of 5- to 10-membered heteroaryl C 1-6 alkyl include, but are not limited to, pyridin-2-ylmethyl, pyridin-4-ylmethyl, 2-(quinolin-8-yl)ethyl, 2-(quinolin-5-yl)ethyl, 2-(quinoxalin-5-yl)ethyl, 2-(1H-indol-3-yl)ethyl, and the like.
  • C 3-20 alicyclic group refers to a monovalent group of a monocyclic , bicyclic, or tricyclic non-aromatic hydrocarbon ring with 3 to 20 carbon atoms, including those that have a partially unsaturated bond, those that have a partially crosslinked structure, those that are partially a spiro, and those having 1 or 2 carbonyl structures.
  • An “alicyclic group” encompasses cycloalkyl, cycloalkenyl, and cycloalkynyl.
  • C 3-20 alicyclic group is preferably a "C 3-10 alicyclic group", more preferably a "C 3-6 alicyclic group”.
  • C 3-20 alicyclic group include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclohexadinyl, cycloheptadinyl, cyclooctadinyl, adamantyl, norbornyl, and the like.
  • C 3-10 alicyclic group refers to a substituent with “C 3-10 alicyclic group” that is a monovalent group among the aforementioned “C 3-20 alicyclic group”.
  • C 3-10 alicyclic oxy refers to an (C 3-10 alicyclic group)-O- group, and the C 3-10 alicyclic moiety is defined the same as a C 3-10 alicyclic group.
  • C 3-6 alicyclic oxy refers to a (C 3-6 alicyclic group)-O- group, and the C 3-6 alicyclic moiety is defined the same as a C 3-6 alicyclic group.
  • C 3-6 alicyclic oxy is preferably "C 3-5 alicyclic oxy”. Specific examples of “C 3-6 alicyclic oxy” include, but are not limited to, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
  • C 3-10 alicyclic carbonyl refers to carbonyl substituted with the "C 3-10 alicyclic group" described above.
  • C 3-10 alicyclic carbonyl is preferably “C 3-6 alicyclic carbonyl”.
  • Specific examples of “C 3-10 alicyclic carbonyl” include, but are not limited to, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, and the like.
  • C 3-10 alicyclic thio refers to a (C 3-10 alicyclic group)-S- group, and the C 3-10 alicyclic moiety is defined the same as a C 3-10 alicyclic group described above.
  • C 3-10 alicyclic thio is preferably "C 3-6 alicyclic thio”.
  • Specific examples of “C 3-6 alicyclic thio” include, but are not limited to, cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio, and the like.
  • C 3-10 alicyclic sulfonyl refers to a sulfonyl group substituted with the "C 3-10 alicyclic group” described above.
  • C 3-10 alicyclic sulfonyl is preferably "C 3-6 alicyclic sulfonyl”.
  • Specific examples of “C 3-10 alicyclic sulfonyl” include, but are not limited to, cyclopropylsulfonyl, cyclobutylsulfonyl, cyclopentylsulfonyl, cyclohexylsulfonyl, and the like.
  • cycloalkyl refers to a non-aromatic saturated hydrocarbon ring group, including those that have a partially crosslinked structure, those that are partially spiro, those having 1 or 2 carbonyl structures.
  • C 3-20 cycloalkyl refers to monocyclic or bicyclic cycloalkyl with 3 to 20 carbon atoms.
  • C 3-6 cycloalkyl refers to monocyclic cycloalkyl with 3 to 6 carbon atoms. Specific examples of C 3-6 cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • cycloalkylalkyl refers to alkyl substituted with at least one cycloalkyl.
  • C 3-6 cycloalkyl C 1-6 alkyl refers to C 1-6 alkyl substituted with at least one C 3-6 cycloalkyl.
  • C 3-6 cycloalkyl C 1-6 alkyl include, but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, 2-cyclopropylethyl, 2-cyclobutylethyl, 2-cyclopentylethyl, 2-cyclohexylethyl, 3-cyclopropylpropyl, 3-cyclobutylpropyl, 3-cyclopentylpropyl, 3-cyclohexylpropyl, and the like.
  • heterocycloalkyl refers to a non-aromatic saturated heterocycle, comprising 1 or more same or different heteroatoms selected from the group consisting of an oxygen atom, nitrogen atom, and sulfur atom, including those that have a partially crosslinked structure and those that are partially spiro.
  • 4- to 20-membered non-aryl heterocycle refers to a monocyclic or bicyclic non-aromatic heterocycle comprised of 4 to 20 atoms, comprising 1 or more same or different heteroatoms selected from the group consisting of an oxygen atom, nitrogen atom, and sulfur atom, including those that have a partially unsaturated bond, those that have a partially crosslinked structure, and those that are partially spiro.
  • a non-aryl heterocycle can form a fused ring with aryl or heteroaryl.
  • a non-aryl heterocycle fused to C 6-10 aryl or 5- to 6-membered heteroaryl is also encompassed by a heterocycle.
  • 1 or 2 carbonyl, thiocarbonyl, sulfinyl, or sulfonyl can be comprised to constitute the non-aryl heterocycle.
  • lactam, thiolactam, lactone, thiolactone, cyclic imide, cyclic carbamate, cyclic thiocarbamate, and other cyclic groups are also encompassed by the non-aryl heterocycle.
  • an oxygen atom of carbonyl, sulfinyl, and sulfonyl and a sulfur atom of thiocarbonyl are not included in the number of 4 to 20 members (ring size) or the number of heteroatoms constituting the ring.
  • 4- to 10-membered non-aryl heterocycle refers to a substituent with “4- to 10-membered non-aryl heterocycle” that is a monovalent group among the "4- to 20-membered non-aryl heterocycle” described above.
  • the 4- to 10-membered non-aryl heterocycle moiety of "4- to 10-membered non-aryl heterocyclyloxy” is defined the same as the "4- to 10-membered non-aryl heterocycle” described above.
  • "4- to 10-membered non-aryl heterocyclyloxy” is preferably "4- to 6-membered non-aryl heterocyclyloxy”.
  • Specific examples of "4-to 10-membered non-aryl heterocyclyloxy” include, but are not limited to, tetrahydrofuranyloxy, tetrahydropyranyloxy, azetidinyloxy, pyrrolidinyloxy, piperidinyloxy, and the like.
  • the 4- to 10-membered non-aryl heterocycle moiety of "4- to 10-membered non-aryl heterocyclylthio” is defined the same as the "4- to 10-membered non-aryl heterocycle” described above.
  • "4- to 10-membered non-aryl heterocyclylthio” is preferably "4- to 6-membered non-aryl heterocyclylthio".
  • Specific examples of "4- to 10-membered non-aryl heterocyclylthio" include, but are not limited to, tetrahydropyranylthio, piperidinylthio, and the like.
  • 4- to 10-membered non-aryl heterocyclylcarbonyl refers to a carbonyl group substituted with the "4- to 10-membered non-aryl heterocycle" described above.
  • “4- to 10-membered non-aryl heterocyclylcarbonyl” is preferably “4- to 6-membered non-aryl heterocyclylcarbonyl”.
  • Specific examples of "4- to 10-membered non-aryl heterocyclylcarbonyl” include, but are not limited to, azetidinylcarbonyl, pyrrolidinylcarbonyl, piperidinylcarbonyl, morpholinylcarbonyl, and the like.
  • 4- to 10-membered non-aryl heterocyclylsulfonyl refers to a sulfonyl group substituted with the "4- to 10-membered non-aryl heterocycle" described above.
  • 4- to 10-membered non-aryl heterocyclylsulfonyl is preferably "4- to 6-membered non-aryl heterocyclylsulfonyl”.
  • 4- to 10-membered non-aryl heterocyclylsulfonyl include, but are not limited to, azetidinylsulfonyl, pyrrolidinylsulfonyl, piperidinylsulfonyl, morpholinylsulfonyl, and the like.
  • heterocycloalkyl refers to heterocycloalkyl comprised of 5 to 6 cyclic atoms, comprising 1 or more same or different heteroatoms selected from the group consisting of an oxygen atom, nitrogen atom, and sulfur atom.
  • heterocycloalkylalkyl refers to alkyl substituted with at least one heterocycloalkyl.
  • Preferred examples of alkylcarbonyl include C 1-6 alkylcarbonyl.
  • alkoxy is a monovalent group of -O-alkyl.
  • Preferred examples of alkoxy include C 1-6 alkoxy (i.e., C 1-6 alkyl-O-), C 1-4 alkoxy (i.e., C 1-4 alkyl-O-), and the like.
  • C 1-4 alkoxy examples include methoxy (CH 3 O-), ethoxy (CH 3 CH 2 O-), n-propoxy (CH 3 (CH 2 ) 2 O-), isopropoxy ((CH 3 ) 2 CHO-), n-butoxy (CH 3 (CH 2 ) 3 O-), isobutoxy ((CH 3 ) 2 CHCH 2 O-), tert-butoxy ((CH 3 ) 3 CO-), sec-butoxy (CH 3 CH 2 CH(CH 3 )O-), and the like.
  • C 1-6 alkoxy include, but are not limited to, C 1-4 alkoxy, n-pentyloxy (CH 3 (CH 2 ) 4 O-), isopentyloxy ((CH 3 ) 2 CHCH 2 CH 2 O-), neopentyloxy ((CH 3 ) 3 CCH 2 O-), tert-pentyloxy (CH 3 CH 2 C(CH 3 ) 2 O-), 1,2-dimethylpropoxy (CH 3 CH(CH 3 )CH(CH 3 )O-), and the like.
  • alkoxycarbonyl include, but are not limited to, C 1-6 alkoxycarbonyl, preferably C 1-4 alkoxycarbony.
  • Specific examples of C 1-4 alkoxycarbonyl include methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl, isobutoxycarbonyl, and the like.
  • C 1-6 alkoxycarbonyl include, but are not limited to, C 1-4 alkoxycarbonyl, n-pentyloxycarbonyl, isopentyloxycarbonyl, neopentyloxycarbonyl, tertpentyloxycarbonyl, 1,2-dimethylpropyloxycarbonyl, n-hexyloxycarbonyl, and the like.
  • alkoxycarbonylamino include, but are not limited to, C 1-6 alkoxycarbonylamino, preferably C 1-4 alkoxycarbonylamino.
  • Specific examples of C 1-4 alkoxycarbonylamino include methoxycarbonylamino, ethoxycarbonylamino, n-propoxycarbonylamino, isopropoxycarbonylamino, n-butoxycarbonylamino, secbutoxycarbonylamino, tert-butoxycarbonylamino, isobutoxycarbonylamino, and the like.
  • C 1-6 alkoxycarbonylamino include, but are not limited to, C 1-4 alkoxycarbonylamino, n-pentyloxycarbonylamino, isopentyloxycarbonylamino, neopentyloxycarbonylamino, tertpentyloxycarbonylamino, 1,2-dimethylpropyloxycarbonylamino, n-hexyloxycarbonylamino, and the like.
  • C 1-6 alkylsulfonyl refers to a sulfonyl group substituted with the "C 1-6 alkyl” described above.
  • C 1 - 6 alkylsulfonyl is preferably “C 1-4 alkylsulfonyl”.
  • Specific examples of “C 1-6 alkylsulfonyl” include, but are not limited to, methylsulfonyl, propionylsulfonyl, butyrylsulfonyl, and the like.
  • C 1-6 alkyl moiety of "C 1-6 alkylthio” is defined the same as the C 1-6 alkyl described above.
  • Examples of “C 1-6 alkylthio” include “C 1-4 alkylthio", and preferred examples thereof include “C 1-3 alkylthio”.
  • C 1-6 alkylthio include, but are not limited to, methylthio, ethylthio, propylthio, butylthio, isopropylthio, isobutylthio, tert-butylthio, sec-butylthio, isopentylthio, neopentylthio, tert-pentylthio, 1,2-dimethylpropylthio, and the like.
  • Preferred examples of arylcarbonyl include C 6-10 arylcarbonyl.
  • C 6-10 aryl moiety of "C 6-10 aryloxy” is defined the same as the C 6-10 aryl described above.
  • Preferred examples of “C 6-10 aryloxy” include “C 6 or C 10 aryloxy”.
  • Specific examples of “C 6-10 aryloxy group” include, but are not limited to, a phenoxy group, 1-naphthyloxy group, 2-naphthyloxy group, and the like.
  • 5- to 6-membered heteroarylcarbonyl group refers to a carbonyl group substituted with the "5-to 6-membered heteroaryl” described above.
  • Specific examples of “5- to 6-membered heteroarylcarbonyl group” include, but are not limited to, pyrazoylcarbonyl group, triazoylcarbonyl group, thiazoylcarbonyl group, thiadiazoylcarbonyl group, pyridylcarbonyl group, pyridazoylcarbonyl group, and the like.
  • the 5- to 6-membered heteroaryl moiety of the "5- to 6-membered heteroaryloxy group” is defined the same as “5-membered heteroaryl” or “6-membered heteroaryl” described above.
  • Specific examples of "5- to 6-membered heteroaryloxy group” include, but are not limited to, a pyrazoyloxy group, triazoyloxy group, thiazoyloxy group, thiadiazoyloxy group, pyridyloxy group, pyridazoyloxy group, and the like.
  • the 5- to 6-membered heteroaryl moiety of "5- to 6-membered heteroarylthio group” is defined the same as “5-membered heteroaryl” or “6-membered heteroaryl” described above.
  • Specific examples of "5- to 6-membered heteroarylthio group” include, but are not limited to, pyrazoylthio group, triazoylthio group, thiazoylthio group, thiadiazoylthio group, pyridylthio group, pyridazoylthio group, and the like.
  • a "5- to 6-membered heteroarylsulfonyl group” refers to a sulfonyl group substituted with a "5- to 6-membered heteroaryl” described above.
  • Specific examples of "5- to 6-membered heteroarylsulfonyl group” include, but are not limited to, pyrazoylsulfonyl group, triazoylsulfonyl group, thiazoylsulfonyl group, thiadiazoylsulfonyl group, pyridylsulfonyl group, pyridazoylsulfonyl group, and the like.
  • a substituent-substituted group means that the group is substituted with at least one substituent.
  • hydroxy-substituted C 1-6 alkyl refers to C 1-6 alkyl that has at least one hydroxy substitution.
  • Examples of “carbamoyl-substituted C 1-6 alkyl” include, but are not limited to, carbamoyl-substituted C 1-4 alkyl.
  • nitrogen protecting group e.g., tert-butoxycarbonyl group.
  • Examples of “amidinoamino-substituted C 1-6 alkyl” include, but are not limited to, “amidinoamino-substituted C 1-4 alkyl” and the like.
  • aminoamino-substituted C 1-4 alkyl examples include, but are not limited to, (amidinoamino)methyl, 2-(amidinoamino)ethyl, 3-(amidinoamino)propyl, 4-(amidinoamino)butyl, and the like.
  • aminodinoamino-substituted C 1-6 alkyl examples include, but are not limited to, amidinoamino-substituted C 1-4 alkyl, 5-(amidinoamino)pentyl, 6-(amidinoamino)hexyl, and the like.
  • amidinoamino groups protected with a nitrogen protecting group examples include
  • Carboxy-substituted C 1-6 alkyl is C 1-6 alkyl substituted with at least one -COOH group.
  • Examples of “carboxy-substituted C 1-6 alkyl” include, but are not limited to, “carboxy-substituted C 1-4 alkyl” and the like.
  • Specific examples of “carboxy-substituted C 1-4 alkyl” include, but are not limited to, carboxymethyl, 2-carboxyethyl, 3-carboxypropyl, 4-carboxybutyl, and the like.
  • Carboxy-substituted C 1-6 alkyl include, but are not limited to, carboxy-substituted C 1-4 alkyl, 5-carboxypentyl, 6-carboxyhexyl, and the like.
  • a “protecting group” refers to a group of atoms that blocks, reduces, or prevents reactivity of a functional group when attached to a reactive functional group in a molecule. Typically, a protecting group can be selectively removed during a synthesis process if desired. Examples of protecting groups are found in Greene and Wuts, Protective Groups in Organic Chemistry, 5th Edition, 2014, John Wiley & Sons, NY and Harrison et al., Compendium of Synthetic Organic Methods, Vol. 1 to 8, John Wiley & Sons, NY , or the like. As used herein, a “protecting group” can fall under the definitions for 1) to 53) of substituent ⁇ and 1) to 26) of substituent ⁇ .
  • nitrogen protecting groups include, but are not limited to, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (“CBZ”), tert-butoxycarbonyl (“Boc”), trimethylsilyl (“TMS”), 2-trimethylsilylethanesulfonyl (“TES”), trityl and substituted trityl group, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (“FMOC”), nitroveratryloxycarbonyl (“NVOC”), and the like.
  • hydroxyl protecting groups include, but are not limited to, groups that acylate (esterify) or alkylate a hydroxyl group, such as benzyl and trityl ether, as well as alkyl ether, tetrahydropyranyl ether, trialkylsilyl ether (e.g., TMS, triethylsilyl, t-butyldimethylsilyl (TBDMS), and triisopropylsilyl (TIPS)), alkylarylsilyl ether (e.g., t-butyldiphenylsilyl (TBDPS)), triarylsilyl ether (e.g., triphenylsilyl), glycol ether (e.g., ethylene glycol ether, propylene glycol ether, and the like), and allyl ether.
  • TMS triethylsilyl
  • TDMS triethylsilyl
  • TDMS t-but
  • the compound of the present disclosure can be exemplified as a compound represented by formula IF: or an enantiomer thereof, or a salt thereof, or a solvate thereof, wherein
  • R 1 , R 2 , and R 3 are each independently optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, or optionally substituted cycloalkylalkyl.
  • R 1 , R 2 , and R 3 are each independently optionally substituted C 1-6 alkyl, optionally substituted C 6-10 aryl C 1-6 alkyl, optionally substituted 5- to 10-membered heteroaryl C 1-6 alkyl, or optionally substituted C 3-6 cycloalkyl C 1-6 alkyl.
  • R 1 , R 2 , and R 3 are each independently optionally substituted alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, or optionally substituted cycloalkylalkyl, and R 4 is hydrogen, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted alkoxycarbonyl, or optionally substituted alkylcarbamoyl.
  • R 1 , R 2 , and R 3 are each independently C 1-6 alkyl, hydroxy-substituted C 1-6 alkyl, carbamoyl-substituted C 1-6 alkyl, amino-substituted C 1-6 alkyl, amidinoamino-substituted C 1-6 alkyl, carboxy-substituted C 1-6 alkyl, C 6-10 aryl C 1-6 alkyl, C 1-4 alkoxycarbonyl-substituted 5-to 10-membered heteroaryl C 1-6 alkyl, C 1-4 alkyl-substituted C 6-10 aryl C 1-6 alkyl, hydroxy-substituted C 6-10 aryl C 1-6 alkyl, halogen-substituted C 6-10 aryl C 1-6 alkyl, C 1-4 alkoxy-substituted C 6-10 aryl C 1-6 alkyl, (optionally substituted amino) -C 6-10
  • R 1 , R 2 , and R 3 are each independently C 1-6 alkyl, hydroxy-substituted C 1-6 alkyl, carbamoyl-substituted C 1-6 alkyl, amino-substituted C 1-6 alkyl, amidinoamino-substituted C 1-6 alkyl, carboxy-substituted C 1-6 alkyl, C 6-10 aryl C 1-6 alkyl, C 1-4 alkoxycarbonyl-substituted 5-to 10-membered heteroaryl C 1-6 alkyl, C 1-4 alkyl-substituted C 6-10 aryl C 1-6 alkyl, hydroxy-substituted C 6-10 aryl C 1-6 alkyl, halogen-substituted C 6-10 aryl C 1-6 alkyl, C 1-4 alkoxy-substituted C 6-10 aryl C 1-6 alkyl, (optionally substituted amino) -C 6-10
  • R 1 , R 2 , and R 3 are each independently alkyl or optionally substituted arylalkyl.
  • R 1 , R 2 , and R 3 are each independently C 1-6 alkyl or optionally substituted C 6-10 aryl C 1-6 alkyl.
  • R 1 , R 2 , and R 3 are each independently C 1-6 alkyl, C 6-10 aryl C 1-6 alkyl, C 1-4 alkyl-substituted C 6-10 aryl C 1-6 alkyl, halogen-substituted C 6-10 aryl C 1-6 alkyl, C 1-4 alkoxy-substituted C 6-10 aryl C 1-6 alkyl, or (optionally substituted amino) -C 6-10 aryl C 1-6 alkyl.
  • R 1 , R 2 , and R 3 are each independently C 1-6 alkyl, C 6-10 aryl C 1-6 alkyl, C 1-4 alkyl-substituted C 6-10 aryl C 1-6 alkyl, chloro-substituted C 6-10 aryl C 1-6 alkyl, C 1-4 alkoxy-substituted C 6-10 aryl C 1-6 alkyl, or (optionally substituted amino) -C 6-10 aryl C 1-6 alkyl.
  • R 1 is C 1-6 alkyl or C 6 aryl C 1-4 alkyl
  • R 2 is C 1-6 alkyl or C 1-4 alkyl-substituted benzyl
  • R 3 is C 1-6 alkyl or C 6 aryl C 1-4 alkyl.
  • R 1 and R 3 are each independently alkyl or optionally substituted benzyl, and R 2 is optionally substituted benzyl.
  • R 1 and R 3 are each independently C 1-6 alkyl, benzyl, C 1-4 alkyl-substituted benzyl, chloro-substituted benzyl, C 1-4 alkoxy-substituted benzyl, or amino-substituted benzyl, and R 2 is benzyl or chloro-substituted benzyl.
  • R 1 and R 3 are each independently isobutyl, isopentyl, 4-(dimethylamino)benzyl, 4-methylbenzyl, 4-methoxybenzyl, 3-chlorobenzyl, 4-chlorobenzyl, or 3,4-dichlorobenzyl, and R 2 is benzyl, 3-chlorobenzyl, or 3,4-dichlorobenzyl.
  • R 1 is isobutyl, benzyl, 4-(dimethylamino)benzyl, 4-methylbenzyl, 4-tert-butylbenzyl, 4-methoxybenzyl, 3-chlorobenzyl, 4-chlorobenzyl, or 3,4-dichlorobenzyl
  • R 2 is isobutyl, benzyl, naphthalen-1-ylmethyl, 4-methylbenzyl, 4-chlorobenzyl, or 3,4-dichlorobenzyl
  • R 3 is isobutyl, isopentyl, or benzyl.
  • R 1 is C 1-6 alkyl, hydroxy-substituted C 1-4 alkyl, carbamoyl-substituted C 1-4 alkyl, amino-substituted C 1-6 alkyl, amidinoamino-substituted C 1-4 alkyl, carboxy-substituted C 1-4 alkyl, C 1-4 alkoxycarbonyl-substituted C 1-4 alkyl, C 6-10 aryl C 1-4 alkyl, hydroxy-substituted C 6-10 aryl C 1-4 alkyl, C 1-4 alkoxy-substituted C 6-10 aryl C 1-4 alkyl, halo-substituted C 6-10 aryl C 1-4 alkyl, or C 5-6 cycloalkyl C 1-4 alkyl.
  • R 1 is methyl, isopropyl, isobutyl, isopentyl, n-hexyl, 3-amino-3-oxopropyl, 3-(tert-butoxy)-3-oxopropyl, benzyl, naphthalen-1-ylmethyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, 4-fluorobenzyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3,4-dichlorobenzyl, naphthalen-1-ylmethyl, phenethyl, hydroxymethyl, 2-hydroxyethyl, or cyclohexylmethyl.
  • R 1 is methyl, isopropyl, isobutyl, isopentyl, n-hexyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, hydroxymethyl, cyclohexylmethyl, or
  • R 1 is methyl, isobutyl, isopentyl, 3-(tert-butoxy)-3-oxopropyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3,4-dichlorobenzyl, or cyclohexylmethyl.
  • R 1 is isopropyl, isobutyl, isopentyl, n-hexyl, cyclohexylmethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, carbamoylethyl, 3-(amidinoamino)propyl, hydroxymethyl, or hydroxyethyl.
  • R 1 is isobutyl, isopentyl, cyclohexylmethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, or hydroxyethyl.
  • R 1 is isobutyl, benzyl, 4-hydroxybenzyl, 2-carboxyethyl, 3-(amidinoamino)propyl, or naphthalen-1-ylmethyl.
  • R 1 is isobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, or
  • R 1 is isobutyl, 3-hydroxypropyl, 3-amino-3-oxopropyl, 6-aminohexyl, 2-carboxyethyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, or cyclohexylmethyl.
  • R 2 is C 1-4 alkyl, hydroxy-substituted C 1-4 alkyl, carbamoyl-substituted C 1-4 alkyl, amino-substituted C 1-4 alkyl, amidinoamino-substituted C 1-4 alkyl, carboxy-substituted C 1-4 alkyl, C 6-10 aryl C 1-4 alkyl, C 1-4 alkoxycarbonyl-substituted 5- to 10-membered heteroaryl C 1-4 alkyl, C 1-4 alkyl-substituted C 6-10 aryl C 1-4 alkyl, hydroxy-substituted C 6-10 aryl C 1-4 alkyl, halogen-substituted C 6-10 aryl C 1-4 alkyl, C 1-4 alkoxy-substituted C 6-10 aryl C 1-4 alkyl, C 1-4 alkoxycarbonyl-substituted C 1-4 alkyl, C
  • R 2 is naphthalen-1-ylmethyl or optionally substituted benzyl.
  • R 2 is isopropyl, 1-methylpropyl, isobutyl, isopentyl, n-hexyl, hydroxymethyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 3-(amidinoamino)propyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 2-(tert-butoxy)-2-oxoethyl, 4-(
  • R 2 is isopropyl, 1-methylpropyl, isobutyl, isopentyl, n-hexyl, hydroxymethyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 2-(tert-butoxy)-2-oxoethyl, 3-(
  • R 2 is isobutyl, 2-hydroxyethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 2-(naphthalen-1-yl)ethyl, 2-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)ethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,4-dichlorobenzyl, 4-(tert-butoxy)benzyl, 2-(tert-butoxy)-2-oxoethyl, 4-((tert-butoxycarbonyl)amino)butyl, (tetrahydro-2H-pyran-2-yl)methyl, or cyclohexylmethyl.
  • R 2 is 1-methylpropyl, isopropyl, isobutyl, isopentyl, n-hexyl, benzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, carbamoylethyl, 3-(amidinoamino)propyl, hydroxymethyl, 2-hydroxyethyl, phenethyl, naphthalen-1-ylmethyl, or cyclohexylmethyl.
  • R 2 is isopropyl, 1-methylpropyl, isobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, or
  • R 2 is isopropyl, isobutyl, isopentyl, benzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, hydroxyethyl, phenethyl, naphthalen-1-ylmethyl, or n-hexyl.
  • R 2 is isobutyl, 2-hydroxyethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, cyclohexylmethyl, or 2-(1H-indol-3-yl) ethyl.
  • R 2 is 1-methylpropyl, isopropyl, isobutyl, benzyl, 4-hydroxybenzyl, 2-carboxyethyl, 3-(amidinoamino)propyl, or naphthalen-1-ylmethyl.
  • R 3 is C 1-4 alkyl, hydroxy-substituted C 1-4 alkyl, carbamoyl-substituted C 1-4 alkyl, C 1-4 alkoxycarbonyl-substituted C 1-4 alkyl, amino-substituted C 1-4 alkyl, amidinoamino-substituted C 1-4 alkyl, carboxy-substituted C 1-4 alkyl, C 6-10 aryl C 1-4 alkyl, C 1-4 alkyl-substituted C 6-10 aryl C 1-4 alkyl, hydroxy-substituted C 6-10 aryl C 1-4 alkyl, or C 5-6 cycloalkyl C 1-4 alkyl.
  • R 3 is isopropyl, isobutyl, isopentyl, n-hexyl, 3-amino-3-oxopropyl, 3-methoxy-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, benzyl, naphthalen-1-ylmethyl, phenethyl, hydroxymethyl, 2-hydroxyethyl, 4-fluorobenzyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-((tert-butoxycarbonyl)amino)butyl, or cyclohexylmethyl.
  • R 3 is isopropyl, isobutyl, isopentyl, n-hexyl, hydroxymethyl, 2-hydroxyethyl, carbamoylmethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 3-(amidinoamino)propyl, 2-carboxyethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-fluorobenzyl, 4-(tert-butoxy)benzyl, 3-methoxy-3-oxopropyl, 3-(tert-butoxy)-3-oxopropyl, 4-((tert-butoxycarbonyl)amino)butyl, cyclohexylmethyl, or
  • R 3 is isobutyl, isopentyl, 3-amino-3-oxopropyl, 3-methoxy-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, phenethyl, 3-methylbenzyl, 4-methylbenzyl, 4-hydroxybenzyl, 4-((tert-butoxycarbonyl)amino)butyl, or cyclohexylmethyl.
  • R 3 is isopropyl, isobutyl, isopentyl, n-hexyl, cyclohexylmethyl, benzyl, phenethyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-fluorobenzyl, 2-carboxyethyl, carbamoylmethyl, carbamoylethyl, 3-(amidinoamino)propyl, hydroxymethyl, or hydroxyethyl.
  • R 3 is isobutyl, isopentyl, benzyl, phenethyl, 4-hydroxybenzyl, 2-carboxyethyl, carbamoylmethyl, 3-(amidinoamino)propyl, hydroxymethyl, or naphthalen-1-ylmethyl.
  • R 3 is isobutyl, benzyl, 4-hydroxybenzyl, 2-carboxyethyl, 3-(amidinoamino)propyl, or naphthalen-1-ylmethyl.
  • R 3 is isobutyl, 2-carboxyethyl, 3-(amidinoamino)propyl, benzyl, naphthalen-1-ylmethyl, 4-hydroxybenzyl, 4-(tert-butoxy)benzyl, 3-(tert-butoxy)-3-oxopropyl, or
  • R 3 is isobutyl, hydroxymethyl, 3-amino-3-oxopropyl, 4-aminobutyl, 2-carboxyethyl, benzyl, 2-naphthylmethyl, 4-hydroxybenzyl, or cyclohexylmethyl.
  • R 1 is C 1-6 alkyl or C 6-10 aryl C 1-6 alkyl
  • R 2 and R 3 are each independently C 1-6 alkyl or optionally substituted C 6-10 aryl C 1-6 alkyl.
  • R 1 is isobutyl, isopentyl, or benzyl
  • R 2 is isobutyl, benzyl, phenethyl, 3-methylbenzyl, 4-methylbenzyl, or 3,4-dichlorobenzyl
  • R 3 is isobutyl, benzyl, phenethyl, 3-methylbenzyl, or 4-methylbenzyl.
  • R 1 is isobutyl
  • R 2 is benzyl
  • R 3 is benzyl
  • R 1 is benzyl
  • R 2 is benzyl
  • R 3 is isobutyl
  • R 1 is isobutyl
  • R 2 is benzyl
  • R 3 is 3-methylbenzyl
  • R 1 is benzyl
  • R 2 is 3,4-dichlorobenzyl
  • R 3 is isobutyl
  • R 1 is isobutyl
  • R 2 is 4-methylbenzyl
  • R 3 is benzyl
  • R 1 is benzyl
  • R 2 is isobutyl
  • R 3 is isobutyl
  • R 4 is hydrogen, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted arylcarbonyl, or optionally substituted alkoxycarbonyl.
  • R 4 is hydrogen, optionally substituted C 1-6 alkyl, optionally substituted C 1-6 alkylcarbonyl, optionally substituted C 6-10 arylcarbonyl, optionally substituted C 1-6 alkoxycarbonyl, or optionally substituted C 1-6 alkylcarbamoyl.
  • R 4 is hydrogen, optionally substituted C 1-6 alkyl, optionally substituted C 1-6 alkylcarbonyl, optionally substituted C 6-10 arylcarbonyl, or optionally substituted C 1-6 alkoxycarbonyl.
  • R 4 is hydrogen, C 1-6 alkyl, C 1-6 alkylcarbonyl, C 6-10 arylcarbonyl, C 1-6 alkoxycarbonyl, or C 1-6 alkylcarbamoyl.
  • R 4 is hydrogen, C 1-6 alkyl, C 1-6 alkylcarbonyl, C 6-10 arylcarbonyl, or C 1-6 alkoxycarbonyl.
  • R 4 is hydrogen, C 1-4 alkyl, C 1-4 alkylcarbonyl, C 6 arylcarbonyl, C 1-4 alkoxycarbonyl, or C 1-4 alkylcarbamoyl.
  • R 4 is hydrogen, C 1-4 alkyl, C 1-4 alkylcarbonyl, C 6 arylcarbonyl, or C 1-4 alkoxycarbonyl.
  • R 4 is hydrogen or alkyl.
  • R 4 is hydrogen or C 1-6 alkyl.
  • R 4 is hydrogen, methyl, ethyl, acetyl, benzoyl, methoxycarbonyl, tert-butoxycarbonyl, or propylcarbamoyl.
  • R 4 is hydrogen, methyl, ethyl, acetyl, benzoyl, methoxycarbonyl, or tert-butoxycarbonyl.
  • R 4 is hydrogen or ethyl. In a preferred embodiment, R 4 is hydrogen.
  • a hydroxyl group, amino group, and /or carboxyl group in R 1 , R 2 , R 3 , and/or R 4 , when present, can be independently protected with a protecting group.
  • Such a compound is also within the scope of the present disclosure.
  • the compound of the present disclosure can be exemplified as a compound represented by formula IB: or an enantiomer thereof, or a salt thereof, or a solvate thereof.
  • R 1 , R 2 , and R 3 in formula IB are defined the same as those in formula IF.
  • the compound of the present disclosure can be exemplified as a compound represented by formula IIF: or an enantiomer thereof, or a salt thereof, or a solvate thereof.
  • R 1 , R 2 , and R 3 in formula IIF are defined the same as those in formula IF.
  • the compound of the present disclosure can be exemplified as a compound represented by formula IIB: or an enantiomer thereof, or a salt thereof, or a solvate thereof.
  • R 1 , R 2 , and R 3 in formula IIB are defined the same as those in formula IF.
  • the compound of the present disclosure can have enantiomers and stereoisomers such as tautomers and geometric isomers depending on the type of substituent, they are also encompassed by the present disclosure. Specifically, if there is one or more asymmetric carbon atoms in the compound of the present disclosure, there is a diastereomer or enantiomer, and a mixture of such a diastereomer and enantiomer, and isolated diastereomers and enantiomers are also encompassed by the compound of the present disclosure.
  • the present disclosure is also intended to encompass various hydrates, solvates, and crystalline polymorphisms.
  • the compound of the present disclosure can be substituted with an isotope (e.g., 2 H (or D), 3 H (or T), 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 35 S, 18 F, 125 I, or the like). These compounds are also encompassed by the compound of the present disclosure.
  • an isotope e.g., 2 H (or D), 3 H (or T), 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 35 S, 18 F, 125 I, or the like.
  • a prodrug refers to a derivative that yields a compound represented by formula IF, IB, IIF, or IIB by acid hydrolysis or enzymatic degradation in the body.
  • a compound represented by formula IF, IB, IIF, or IIB has a hydroxyl group, amino group, or carboxyl group, these groups can be modified by a conventional method to manufacture a prodrug.
  • Prodrug technologies are described in, for example, C.G. Wermuth, "The Practice of Medicinal Chemistry", 4th Ed., Academic Press, (2015), Chapter 28 .
  • Examples for compounds having a carboxy group include compound whose carboxyl group is modified to be an alkoxycarbonyl group, alkylthiocarbonyl group, or alkylaminocarbonyl group.
  • Examples of compounds having an amino group include compounds whose amino group is substituted with an alkanoyl group to be an alkanoylamino group, compounds substituted with an alkoxycarbonyl group to be an alkoxycarbonylamino group, compounds modified to have an alkanoyloxymethylamino group, and compounds modified to have hydroxylamine.
  • Examples for compounds having a hydroxyl group include compounds whose hydroxyl group is substituted with an alkanoyl group to be an alkanoyloxy group, phosphate ester, or alkanoyloxymethyloxy group.
  • alkyl moiety of a group used for preparing a prodrug thereof examples include the alkyl group.
  • the alkyl group is optionally substituted with, for example, an alkoxy group or the like. Preferred examples thereof include the following.
  • examples thereof include alkoxycarbonyl such as methoxycarbonyl and ethoxycarbony, and alkoxycarbonyl substituted with an alkoxy group such as methoxymethoxycarbonyl, ethoxymethoxycarbonyl, 2-methoxyethoxycarbonyl, and 2-methoxyethoxymethoxycarbonyl, or privaloyloxymethoxycarbonyl.
  • pharmaceutically acceptable salt refers to an acid addition salt or base addition salt which is pharmaceutically acceptable for use.
  • pharmaceutically acceptable salts include, but are not limited to, acid addition salts such as acetate, propionate, butyrate, formate, trifluoroacetate, maleate, fumarate, tartrate, citrate, stearate, succinate, ethylsuccinate, malonate, lactobionate, gluconate, glucoheptonate, benzoate, methanesulfonate, benzenesulfonate, para-toluenesulfonate (tosylate), laurylsulfate, malate, ascorbate, mandelate, saccharinate, xinafoate, pamoate, cinnamate, adipate, cysteine salt, N-acetyl cysteine salt, hydrochloride, hydrobromide, phosphate, sulf
  • the compound of the present disclosure can be administered directly, or as a formulation, medicament, or a pharmaceutical composition using a suitable dosage form, by oral or parenteral administration.
  • suitable dosage forms include, but are not limited to, tablets, capsules, powdered agents, granules, liquid agents, suspension, injection agents, patch-on agents, poultice, and the like.
  • These formulations can be manufactured by a known method using an additive that is commonly used as a pharmaceutical additive.
  • an excipient disintegrant, binding agent, fluidizer, lubricant, coating agent, solubilizing agent, solubilizing promotor, thickener, dispersant, stabilizer, sweetener, flavoring agent, or the like can be used depending on the objective.
  • additives include, but are not limited to, lactose, mannitol, crystalline cellulose, low-substituted hydroxypropyl cellulose, corn starch, partially pregelatinized starch, carmellose calcium, croscarmellose sodium, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl alcohol, magnesium stearate, sodium stearyl fumarate, polyethylene glycol, propylene glycol, titanium oxide, talc, and the like.
  • the dosage of the compound of the present disclosure is appropriately selected depending on the subject targeted for administration, route of administration, disease, age of subject, body weight, and symptom.
  • the dosage is 0.01 mg as the lower limit (preferably 100 mg) and 10000 mg as the upper limit (preferably 6000 mg) per day for adults for oral administration. This amount can be administered once daily, or divided into several doses.
  • the compound of the present disclosure is a compound with an antiviral activity for a virus in the Lyssavirus genus.
  • the virus in the Lyssavirus genus comprises a rabies virus, Lagos bat virus, mokola virus, Duvenhage virus, European bat 1 lyssavirus, European bat 2 lyssavirus, Australian bat lyssavirus, and the like.
  • the virus in the Lyssavirus genus preferably comprises a rabies virus.
  • the timing of dosing of the compound of the present disclosure and therapeutic agents thereof is not limited.
  • the compound and therapeutic agent can be administered concurrently or sequentially to a subject being administered therewith.
  • the compound of the present disclosure and therapeutic agent thereof can be formulated as a combined agent.
  • the dosage of the therapeutic agent can be appropriately selected based on the clinically used dose.
  • the ratio of the compound of the present disclosure and therapeutic agent thereof can be appropriately selected depending on the subject of administration, route of administration, target disease, symptom, combination, or the like.
  • the compound of the present disclosure can be combined and administered concurrently or at different times upon use of a pharmaceutical composition.
  • a pharmaceutical composition is also within the scope of the present disclosure.
  • Such a medicament, formulation, or pharmaceutical composition can be manufactured by mixing the compound of the present disclosure and/or an addition agent (e.g., anti-rabies gamma globulin formulation, antimicrobial agent, antiviral agent (e.g., ribavirin, amantadine, or the like), sedative (e.g., ketamine, midazolam, or the like) or the like) with any suitable component, together or separately, as a combined agent, or as separate agents using any technology that is known in the art.
  • an appropriate formulation such as a tablet, capsule, powder, granule, liquid agent, suspension, injection, patch, or poultice can be formulated by using any technology that is known in the art.
  • an addition agent e.g., anti-rabies gamma globulin formulation, antimicrobial agent, antiviral agent (e.g., ribavirin, amantadine, or the like), sedative (e.g., ketamine, midazolam, or the like) or the like
  • an addition agent e.g., anti-rabies gamma globulin formulation, antimicrobial agent, antiviral agent (e.g., ribavirin, amantadine, or the like), sedative (e.g., ketamine, midazolam, or the like) or the like
  • an addition agent e.g., anti-rabies gamma globulin formulation, antimicrobial agent, antiviral agent (e.g., ribavirin, amantadine, or the like), sedative (e.g., ketamine, midazolam, or the like) or the like
  • the kit can provide one of the components as a single agent, with instructions (package insert or the like) instructing to combine and administer the other component (for the compound of the present disclosure, the additional agent; for the addition agent (e.g., anti-rabies gamma globulin formulation, antimicrobial agent, antiviral agent (e.g., ribavirin, amantadine, or the like), sedative (e.g., ketamine, midazolam, or the like) or the like), the compound of the present disclosure) concurrently or at different times.
  • the addition agent e.g., anti-rabies gamma globulin formulation, antimicrobial agent, antiviral agent (e.g., ribavirin, amantadine, or the like), sedative (e.g., ketamine, midazolam, or the like) or the like
  • the compound of the present disclosure concurrently or at different times.
  • the compound of the present disclosure is used as an active ingredient of a medicament, the compound is intended for use in not just humans, but also other animals other than humans (cat, dog, cow, horse, bat, fox, mangoose, raccoon, and the like).
  • the compound of the present disclosure can be manufactured by, for example, the following manufacturing methods, but are not limited to such methods. These manufacturing methods can be appropriately improved upon based on the expertise of those skilled in the art of organic synthetic chemistry. Salts of the compounds used as a raw material can be used in the following manufacturing method, as long as the reaction is not affected.
  • a functional group other than those at the reaction point can be protected as needed and deprotected after the completion of a reaction or after a series of reations to obtain a compound of interest if one of the functional groups other than those at the reaction point is altered under the reaction condition or if it is unsuitable for post-reaction processing.
  • Common protecting groups described in the document Peter G. M. Wuts, "Greene's Protective Groups in Organic Synthesis", 5th Ed., John Wiley & Sons, Inc., Hoboken, New Jersey (2014 )
  • a protecting group can be introduced or removed by a method that is commonly used in organic synthetic chemistry (e.g., method described in the aforementioned document or the like) or a method in accordance thereto.
  • the starting material and intermediate in the following manufacturing methods can be purchased as a commercially available product or are available by synthesis in accordance with a method described in a known document or a known method from a known compound. Salts of the starting material and intermediate can also be used, as long as the reaction is not affected.
  • the intermediate and compound of interest in the following manufacturing methods can also be converted into another compound encompassed by the present disclosure by appropriately converting their functional groups.
  • a functional group can be converted in doing so by a method that is commonly used in organic synthetic chemistry (e.g., method described in R. C. Larock, "Comprehensive Organic Transformations", 2nd Ed., John Wiley and Sons, Inc., New York (1999 ) or the like) or a method in accordance therewith.
  • An inert solvent in the following manufacturing methods refers to a solvent that does not react with a raw material, reagent, base, acid, catalyst, ligand, or the like used in the reaction (hereinafter, also referred to as "raw material or the like used in the reaction").
  • a solvent used in each step can be used as an inert solvent even if the solvent reacts with the raw material or the like used in the reaction, as long as the reaction of interest proceeds to result in a compound of interest.
  • Compound III can be manufactured by, for example, the following manufacturing method.
  • X L represents a leaving group in a nucleophilic substitution reaction, which generally represents halogen (e.g., chlorine, bromine, or iodine) and sulfonyl-O- groups (e.g., methanesulfonyl-O-, toluenesulfonyl-O-, and the like).
  • halogen e.g., chlorine, bromine, or iodine
  • sulfonyl-O- groups e.g., methanesulfonyl-O-, toluenesulfonyl-O-, and the like.
  • R 1 in compound III can be expressed as -CH 2 -R 1 ', R 1 in compound III can be replaced with -CH 2 -R 1 ' to express compound III as compound III'.
  • R 1 is as defined in item 1 herein, and "Protect” is a protecting group of amino group.
  • protecting groups of an amino group include an ethoxycarbonyl group, tert-butoxycarbonyl group, acetyl group, benzoyl group, trifluoroacetyl group, benzyloxycarbonyl group, 3- or 4-chlorobenzyloxycarbonyl group, triphenylmethyl group, methanesulfonyl group, p-toluenesulfonyl group, trimethylsilyl group, benzyloxycarbonyl group, 3- or 4-chlorobenzyloxycarbonyl group, benzylsulfonyl group, benzyl group, 4-nitrobenzyl group, 4-methoxybenzyl group, methyl group, ethyl group, and the like.
  • a compound that is commercially available or a compound manufactured by a known method can be used as a starting raw material compound.
  • a compound of formula V can be manufactured by, for example, the following manufacturing method.
  • R 8 indicates alkoxy, aryloxy, hydroxy, or halogen. Examples thereof include an ethoxy group. This systhesis is achieved by various reactions known to those skilled in the art. If R 2 is aryl, compound V can be synthesized in accordance with the method described in C. W. Cheung, M. L. Ploeger, and X. Hu, Nature Communications 2017, 8, 14878 .
  • R 2 is as defined in item 1 herein.
  • a compound that is commercially available or a compound that is manufactured by a known method can be used as the starting compound.
  • a compound of formula VI can be manufactured from compound III and compound IV by, for example, the following manufacturing method. wherein R 1 and R 3 are as defined in item 1 herein.
  • a compound of formula IIF and compound of formula IIB can be manufactured, for example, from three components through one-pot synthesis in accordance with a known method (e.g., method described in Bioorg. Med. Chem. 23 (2015) 2629-2635 , Tetrahedron 63 (2007) 6004-6014 , Eur. J. Org. Chem. 2009, 2185-2189 , Eur. J. Org. Chem. 2011, 2354-2359 or the like).
  • R 1 , R 2 , and R 3 are as defined in item 1 herein.
  • a compound of formula IIF and compound of formula IIB can be manufactured, for example, from two components as described below. wherein R 1 , R 2 , and R 3 are as defined in item 1 herein.
  • Compound IF i.e., compound of formula IF
  • compound IB i.e., compound of formula IB
  • R 4 therein is H.
  • Amine of a piperidine ring of compound IF or compound IB can be modified, for example by alkylation, amidation, or the like as follows.
  • the intermediate and compound of interest in the manufacturing methods described above can be isolated and purified by subjecting them to a purification method that is commonly used in organic synthesis chemistry (e.g., neutralization, filtration, extraction, washing, drying, concentration, recrystallization, various chromatography, or the like). Each intermediate can also be subjected to the subsequent reaction without any particular purification.
  • a purification method that is commonly used in organic synthesis chemistry (e.g., neutralization, filtration, extraction, washing, drying, concentration, recrystallization, various chromatography, or the like).
  • Each intermediate can also be subjected to the subsequent reaction without any particular purification.
  • Optically active forms of the compound of the present disclosure can be manufactured by using an optically active starting material or intermediate, or by optically resolving a racemate of the final product or intermediate.
  • optional resolution methods include, but are not limited to, separation method using an optically active column or a separation method such as fractional crystallization method.
  • a diastereomer of the compound of the present disclosure can be manufactured by, for example, but not limited to, a separation method such as column chromatography or fractional crystallization.
  • a pharmaceutically acceptable salt of a compound represented by formula IF, IB, IIF, or IIB can be manufactured by, for example, but not limited to, mixing a compound represented by formula (1) with a pharmaceutically acceptable acid or base in a solvent such as water, methanol, ethanol, 2-prpanol, ethyl acetate, or acetone.
  • a solvent such as water, methanol, ethanol, 2-prpanol, ethyl acetate, or acetone.
  • TLC Thin Layer Chromatography
  • Merck's TLC Silica gel 60 F254 25 glass plate, 20 ⁇ 20 cm
  • Fuji Silysia Chemical's CHROMATOREX NH-TLC Plates (20 ⁇ 20 cm) were used.
  • chloroform-methanol mixed solvent system chloroform-methanol mixed solvent system, ethyl acetate-methanol mixed solvent system, or ethyl acetate-hexane mixed solvent system was used. Spots were checked using coloring with UV irradiation, ninhydrin, iodine, or phosphomolybdic acid (ethanol solution).
  • An organic solvent was dried using anhydrous sodium sulfate and anhydrous magnesium sulfate.
  • Fuji Silysia Chemical's cartridge column CHROMATOREX Q-PACKS 130 (SIZE 10, 20, or 60) and DNH (SIZE 20) or Shoko Science's Purif-Pack ® -EX SI50 (SIZE 20 or 60) were used in accordance with the amount of raw product to be purified.
  • Nuclear Magnetic Resonance was measured using Bruker AVANCE III 400 MHz Spectrometer (resonant frequency: 1 H: 400 MHz, 13 C: 100 MHz) and Bruker AVANCE III 300 MHz Spectrometer (resonant frequency: 1 H: 300 MHz, 13 C: 75 MHz) .
  • X-ray crystal structure Rigaku Corporation's single crystal X-ray diffractometer XtaLAB P200 was used. Cu-K ⁇ rays monochromed with a multilayer mirror were used as the source.
  • the structure was determined by a direct method using SIR2008.
  • the structure was refined by the full-matrix least-squares method with respect to F2 using SHELEX-2014/7. Non-hydrogen atoms were refined with anisotropic atomic displacement parameters.
  • Ethyl 1,2,4-triazine-3-carboxylate (1.53 g,10.0 mmol) was dissolved in methanol (10.0 mL), and phenylmethaneamine (1.18 g, 11.0 mmol) was added. The mixture was then stirred for 3 hours at 50°C. Methanol was evaporated under reduced pressure, and the resulting residue was purified by column chromatography (column: Purif-Pack Si50, Size 60, eluent: ethyl acetate-methanol (gradient from 0% to 15%)). A fraction of a compound of interest was concentrated. The eluted crystal was filtered out to obtain the aforementioned compound (1.25 g, yield: 58%).
  • Triethylamine (0.245 mL, 1.75 mmol) was added to an ethanol (2.00 mL) solution of tert-butyl 3-aminopropanoate ⁇ HCl (272 mg, 1.50 mmol).
  • Prop-2-en-1-amine (3.42 g, 60.0 mmol) was added dropwise to a methanol (40.0 mL) solution of cyclohexanecarbaldehyde (7.06 g, 63.0 mmol) while cooling with ice.
  • sodium tetrahydroborate (0.850 g, 22.0 mmol) was added portionwise while cooling with ice, and the mixture was stirred for another hour.
  • Methanol was evaporated under reduced pressure.
  • Ethyl ether was added to the residue. The organic layer was washed with saturated saline and dried with anhydrous sodium sulfate and then concentrated under reduce pressure. The residue was evaporated under reduced pressure to obtain the aforementioned compound (7.35 g, 80%, boiling point, 79 to 84°C/9.1 mmHg).
  • Tables 1 to 4 summarize the synthesized compounds of formula IIB and compounds of IIF. The following abbreviations are used in the following tables.
  • Figure 1 shows an ORTEP diagram thereof. Daicel Corporation's chiral column, CHIRALPAK IG (5 ⁇ m, 4.6 ⁇ 150 mm), mobile phase: methanol: diethylamine (100:0.1) was used to confirm that the molecule was a racemate through analysis.
  • Figure 2 shows the chromatogram thereof.
  • Triethylamine (0.0156 mL, 1.13 mmol) and acetyl chloride (0.00804 mL, 1.13 mmol) were added to a tetrahydrofuran (1.80 mL) solution of (3S*,3aS*, 6S*,7R*,7aS*)-N,7-dibenzyl-1-isobutyloctahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide (IF-1) (31.4 mg, 0.0751 mmol), and stirred for 30 minutes while cooling with ice.
  • IF-1 31.4 mg, 0.0751 mmol
  • Triethylamine (0.0152 mL, 0.110 mmol) and benzoyl chloride (0.0127 mL, 1.10 mmol) were added to a tetrahydrofuran (2.00 mL) solution of (3S*,3aS*,6R*,7R*,7aS*)-N,7-dibenzyl-1-isobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-1) (30.6 mg, 0.0733 mmol) and stirred for 30 minutes while cooling with ice.
  • IB-1 30.6 mg, 0.0733 mmol
  • Triethylamine (0.0157 mL, 0.113 mmol) and methyl chloroformate (0.00870 mL, 0.113 mmol) were added to a tetrahydrofuran (2.00 mL) solution of (3S*, 3aS*, 6R*, 7R*, 7aS*) -N, 7-dibenzyl-1-isobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide (IB-1) (31.5 mg, 0.0754 mmol), and stirred for 30 minutes while cooling with ice.
  • IB-1 7-dibenzyl-1-isobutyloctahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide
  • N,N-dimethylformamide (1 mL) was added to 4-methylpentanal (60.1 mg, 0.6 mmol), tert-butyl(3-(allylamino)propyl)carbamate (128.6 mg, 0.6 mmol), and molecular sieve 4A (100 mg), and then N-(naphthalen-1-ylmethyl)-1,2,4-triazine-3-carboxamide (79.3 mg, 0.3 mmol) was added.
  • the reaction mixture was heated for 16 hours at 85°C, and then filtered.
  • the filtrate was purified by preparative HPLC (High Performance Liquid Chromatography). A fraction of the substance of interest was concentrated to obtain a mixture of the aforementioned compound.
  • Trifluoroacetic acid (0.3 mL) was added to the compound (mixture) obtained in 1. and stirred for 1 hour at room temperature. The trifluoroacetic acid was evaporated to obtain a trifluoroacetic acid salt of the aforementioned compound (mixture).
  • 1,3-di(tert-butoxycarbonyl)-2-(trifluoromethanesulfonyl)guanidine 234.8 mg, 0.6 mmol
  • triethylamine 60.7 mg, 0.6 mmol
  • tetrahydrofuran 0.5 mL
  • reaction mixture obtained in 3. was dissolved in methanol (1 mL), then sodium borohydride (22.7 mg, 0.6 mmol) was added and stirred for 2 hours at room temperature.
  • the reaction mixture was purified by preparative HPLC. Fractions of substances of interest were concentrated to obtain each of the aforementioned compounds separately.
  • Trifluoroacetic acid (0.3 mL) was added to (3S*, 3aS*, 6S*, 7R*, 7aS*) -1- (3- (N, N'-di (tert-butoxycarbonyl)guanidino)propyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)octahydro-6H-3,6-methanopyrrolo[3,2-c]pyridine-6-carboxamide obtained in 4. and stirred for 1 hour at room temperature. The trifluoroacetic acid was evaporated to obtain a trifluoroacetic acid salt of the aforementioned compound.
  • a trifluoroacetic acid salt of the aforementioned compound was obtained by the same method as 5. by using (3S*, 3aS*, 6R*, 7R*, 7aS*) -1- (3- (N, N'-di (tert-butoxycarbonyl)guanidino)propyl)-7-isobutyl-N-(naphthalen-1-ylmethyl)octahydro-3aH-3,6-methanopyrrolo[3,2-b]pyridine-3a-carboxamide obtained in 4.
  • reaction mixture was concentrated and ethyl acetate was added, and then transferred to a separatory funnel and washed with saturated saline.
  • Tables 3 and 4 summarize the synthedized compounds of formula IB and compounds of IF.
  • EX means that the synthesis method is described in the Examples.
  • [Table 3-1] Compou nd number R 1 R 2 R 3 R 4 Synthes is method Intermedia te IB-1 i-Bu Bnzl Bnzl H EX IIB-1 IB-2 i-Bu i-Bu i-Bu H IB-1 IIB-2 IB-3 i-Bu i-Bu Bnzl H IB-1 IIB-3 IB-4 Bnzl i-Bu i-Bu H IB-1 IIB-4 IB-5 i-Bu Bnzl i-Bu H IB-1 IIB-5 IB-6 Bnzl i-Bu Bnzl H IB-1 IIB-6 IB-7 Bnzl Bnzl i-Bu H IB-1 IIB-7 IB-8 Bnzl Bnzl Bnzl H IB-1 IIB-8 IB-9 i-Pnt
  • Each tested compound prepared as a 10 mM with DMSO was first diluted to 100 ⁇ M or 40 ⁇ M with 10% fetal bovine serumsupplemented Eagle's minimal essential medium (hereinafter, medium), and further diluted with the medium to the final concentration of interest. Fifty microlitter of the diluted medium was added dropwise to each well of a 96-well plate. Furthermore, 50 ⁇ L of medium comprising 4 ⁇ 10 2 infectious units of the recombinant rabies virus 1088 strain expressing Gaussia Luciferase (GLuc) (1088/GLuc) and 4 ⁇ 10 4 Neuro-2a cells were added to each well.
  • GLuc Gaussia Luciferase
  • the plate was shaken for 30 seconds with a multiple microplate mixer NS-4P (AS ONE Corporation) and then cultured for 3 days at 37°C in the presence of 5% CO 2 . After incubation, 25 ⁇ L of coelenterazine, which is a substrate of the luciferase, was added dropwise to each well of the plate, and the plate was immediately loaded into a luminescent plate reader LuMate (Awareness Technology) and shaken for 10 seconds. The relative light unit (RLU) was then measured.
  • Anti-rabies activity of compound of formula IB (A: IC 50 ⁇ 5 ⁇ M, B: 5 ⁇ M ⁇ IC 50 ⁇ 10 ⁇ M, C: 10 ⁇ M ⁇ IC 50 ⁇ 30 ⁇ M)
  • Compound number R 1 R 2 R 3 R4 Anti-rabies activity IB-3 i-Bu i-Bu Bnzl H C IB-4 Bnzl i-Bu i-Bu H C IB-5 i-Bu Bnzl i-Bu H C IB-9 i-Pnt Bnzl Bnzl H C IB-12 i-Bu phenethyl Bnzl H C IB-13 i-Bu Bnzl 3-methylbenz yl H C IB-15 i-Bu 3-methylbenz yl Bnzl H C IB-42 Np-M Bnzl Bnzl H C IB-81 carbamoylmeth yl 1-naphthylme thyl i-Bu
  • Anti-rabies activity of compounds of formulas IIB and IIF (A: IC 50 ⁇ 5 ⁇ M, B: 5 ⁇ M ⁇ IC 50 ⁇ 10 ⁇ M, C: 10 ⁇ M ⁇ IC 50 ⁇ 30 ⁇ M)
  • Anti-rabies activity IIB-4 Bnzl i-Bu i-Bu B IIB-83 4-Cl-Bnzl Bnzl i-Bu A IIB-84 3-Cl-Bnzl Bnzl i-Bu A IIB-85 4-methoxybenzyl Bnzl i-Bu B IIB-86 4-methylbenzyl Bnzl i-Bu B IIB-94 4-(dimethylamino)benzyl Bnzl i-Bu B IIB-95 4- (tert-butyl)benzyl Bnzl i-Bu B IIB-96 4-(trifluoromethoxy)benz yl Bnz
  • Recombinant rabies virus 1088 strain expressing Red Firefly Luciferase (RFLuc) (1088/RFLuc) was generated by replacing the E2Cr gene of the recombinant virus 1088/E2Cr with the RFLuc gene ( Isomura M, Yamada K, Noguchi K, Nishizono A. Near-infrared fluorescent protein 1RFP720 is optimal for in vivo fluorescence imaging of rabies virus infection. J Gen Virol. 2017, 98(11): 2689-2698. doi: 10.1099/jgv.0.000950 .).
  • mice were monitored for clinical signs and weighed everyday.
  • the viral dynamics in the treated mice were observed longitudinally using in vivo imaging as follows; mice were administered D-Luciferin solution (150 mg/kgBW; Wako Pure Chemical Industry) intraperitoneally and then imaged (exposure time of 2 minutes and electron-multiplying gain of 300) with the Lumazone imaging system (Nippon Roper) under 2% isoflurane inhalation anesthesia after 15 minutes of substrate injection.
  • the obtained images (16-bit TIFF) were processed and analysed using the ImageJ software.
  • the compounds listed in Table 5 that were evaluated in Example 2 were tested as the test compounds.
  • favipiravir product name: Avigan tablet/Toyama Chemical
  • favipiravir product name: Avigan tablet/Toyama Chemical
  • a significant prophylactic effect was confirmed in ddY mice given in a dose of 300 mg/kgBW/day, but not 100 mg/kgBW/day, for 7 days immediately after viral inoculation
  • the present compound can be provided as a novel and highly effective rabies therapeutic agent that has a different mechanism of action from favipiravir.
  • the present disclosure is useful in the field of rabies treatment and prophylaxis.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP19849263.9A 2018-08-16 2019-08-15 Compound for treatment of rabies and method for treatment of rabies Active EP3838901B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018153227 2018-08-16
PCT/JP2019/032032 WO2020036211A1 (ja) 2018-08-16 2019-08-15 狂犬病の治療のための化合物およびその方法

Publications (3)

Publication Number Publication Date
EP3838901A1 EP3838901A1 (en) 2021-06-23
EP3838901A4 EP3838901A4 (en) 2022-04-06
EP3838901B1 true EP3838901B1 (en) 2023-09-27

Family

ID=69524765

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19849263.9A Active EP3838901B1 (en) 2018-08-16 2019-08-15 Compound for treatment of rabies and method for treatment of rabies

Country Status (6)

Country Link
US (2) US11292794B2 (ja)
EP (1) EP3838901B1 (ja)
JP (2) JP6679059B1 (ja)
CN (2) CN112839944B (ja)
TW (1) TW202021964A (ja)
WO (1) WO2020036211A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6890865B1 (ja) * 2019-06-03 2021-06-18 株式会社大分大学先端医学研究所 狂犬病治療のための環状アミド化合物およびその方法
CN115052661A (zh) * 2020-02-14 2022-09-13 株式会社大分大学先端医学研究所 化合物和利用其的药物
EP4261830A1 (en) * 2020-12-09 2023-10-18 Oita University Institute of Advanced Medicine, Inc. Novel peptidomimetic compound and design
IL309571A (en) * 2021-06-26 2024-02-01 Cedilla Therapeutics Inc CDK2 inhibitors and methods of using them

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010029313A1 (en) * 2008-09-11 2010-03-18 Summit Corporation Plc. Antiinfective compounds
US9879003B2 (en) * 2012-04-11 2018-01-30 Dana-Farber Cancer Institute, Inc. Host targeted inhibitors of dengue virus and other viruses
JP6277503B1 (ja) 2017-03-15 2018-02-14 株式会社コナミデジタルエンタテインメント サーバ装置、及びそれに用いられるコンピュータプログラム
JP6890865B1 (ja) * 2019-06-03 2021-06-18 株式会社大分大学先端医学研究所 狂犬病治療のための環状アミド化合物およびその方法

Also Published As

Publication number Publication date
CN112839944A (zh) 2021-05-25
US11292794B2 (en) 2022-04-05
US11780841B2 (en) 2023-10-10
JP2020109104A (ja) 2020-07-16
JP6679059B1 (ja) 2020-04-15
CN112839944B (zh) 2022-08-05
US20210214356A1 (en) 2021-07-15
EP3838901A1 (en) 2021-06-23
EP3838901A4 (en) 2022-04-06
WO2020036211A1 (ja) 2020-02-20
JPWO2020036211A1 (ja) 2020-08-27
US20220194942A1 (en) 2022-06-23
TW202021964A (zh) 2020-06-16
CN115260193A (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
EP3838901B1 (en) Compound for treatment of rabies and method for treatment of rabies
KR102075886B1 (ko) 신규한 피라졸로[3,4-d]피리미딘 화합물 또는 그 염
KR101738866B1 (ko) 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n'-다이아릴티오우레아 및 n,n'-다이아릴우레아, 이의 제조방법 및 이의 용도
TW202206423A (zh) 用於突變體ras降解之化合物
CA2135597A1 (en) Glutaminase inhibitor
JP6890865B1 (ja) 狂犬病治療のための環状アミド化合物およびその方法
EP4043457A1 (en) Aromatic heterocyclic compound having tricyclic structure, and preparation method therefor and application thereof
KR102537616B1 (ko) 히스톤 탈아세틸화 효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
EP4104902A1 (en) Compound and drug containing same
JPH06329678A (ja) 多環式化合物及びその製造方法
WO2023130012A1 (en) Compounds for mutant kras protein degradation and uses thereof
CN109438347B (zh) 一种氰基喹啉类ido1抑制剂、其制备方法及应用
KR20230106637A (ko) 빈혈 및 암 치료용 vhl 억제제로서의 1-(2-(4-시클로프로필-1h-1,2,3-트리아졸-1-일)아세틸)-4-히드록시-n-(벤질)피롤리딘 e-2-카르복사미드 유도체
TWI843372B (zh) 用於降解突變kras蛋白之化合物及其應用
EP4353724A1 (en) Compound as cdk kinase inhibitor and use thereof
EP4159736A1 (en) Novel tricyclic aromatic heterocyclic compound and preparation method therefor, pharmaceutical composition and use thereof
JP2002308870A (ja) チオフェン骨格を有する抗菌剤
CN117820236A (zh) 组蛋白乙酰转移酶小分子抑制剂及其制备方法和用途
CN110963991A (zh) 一种pi3k抑制剂及其制备方法和应用
WO2019169011A1 (en) Chemotherapeutic oligopeptide mimetics
JPH07126279A (ja) アシルアミノ糖誘導体及びその製法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210305

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OITA UNIVERSITY INSTITUTE OF ADVANCED MEDICINE, INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: YOSHIMORI ATSUSHI

Inventor name: MISHINA TADASHI

Inventor name: NISHIZONO AKIRA

Inventor name: MATSUOKA SHIGERU

Inventor name: ISHIZAKI TOSHIMASA

Inventor name: KATOH AKIRA

Inventor name: YAMADA KENTARO

Inventor name: KOUJI HIROYUKI

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220304

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/14 20060101ALI20220228BHEP

Ipc: C07D 487/18 20060101ALI20220228BHEP

Ipc: A61K 31/439 20060101ALI20220228BHEP

Ipc: C07D 471/08 20060101AFI20220228BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20221109

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IRIMAJIRI THERAPEUTICS INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230414

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230811

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602019038376

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230927

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230927

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231227

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230927

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230927

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230927

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231228

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230927

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20230927

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1615349

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230927

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230927

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230927

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230927

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230927

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230927

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240127

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230927

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230927

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230927

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230927

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240129

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230927

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230927

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230927